Announcement of Abnormal Stock Trading Fluctuations
Securities Code: 300204
Securities Abbreviation: Shutai Shen
Announcement Number: 2026-007
Shenzhen Shutai Shen Biopharmaceutical Co., Ltd. and all members of the board guarantee that the content of this information disclosure is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
Important Content Reminder:
- The stock of Shenzhen Shutai Shen Biopharmaceutical Co., Ltd. has experienced a cumulative price increase exceeding 30% over three consecutive trading days (March 27, 2026, March 30, 2026, and March 31, 2026). According to the Shenzhen Stock Exchange trading rules and related regulations, this constitutes an abnormal trading fluctuation.
- The board has verified that as of the date of this announcement, there are no undisclosed significant matters regarding the company, its controlling shareholders, or actual controllers, and there have been no stock trading activities during the period of abnormal fluctuations.
- Risk Reminder: Since 2020, the company has maintained a high level of R&D investment. However, due to a decline in operating income, the net profit attributable to shareholders of the listed company and the net profit after deducting non-recurring gains and losses have been negative in each reporting period, indicating a long-term loss situation. The company disclosed its 2025 annual performance forecast on January 28, 2026 (Announcement Number: 2026-002), and as of the date of this announcement, there are no corrections needed for the aforementioned performance forecast. According to the 2025 annual performance forecast, due to external environment and industry policy factors, the income from the company's product Shutaiqing has declined, leading to an overall decrease in operating income, with a projected net profit for the reporting period being negative. The company plans to disclose its 2025 annual report on April 28, 2026; please pay attention to the company's regular reports for specific operational conditions and financial data. The company has multiple ongoing projects that are innovative bioproducts. Innovative biomedicine is characterized by high technology, high risk, and high added value, with long and complex cycles from development, clinical trials, approval to production, and is easily affected by various factors such as technology, approval, and policy, facing risks such as clinical trial progress not meeting expectations, clinical trial results not meeting expectations, and drug application approvals not meeting expectations. Investors are advised to make cautious decisions and pay attention to investment risks.